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Abstract Daunorubicin induces apoptosis in myeloid leukemia
cells by activation of neutral sphingomyelinase and ceramide
generation occurring 4^10 min after daunorubicin addition. We
show here that daunorubicin is able to increase the phosphoinosi-
tide 3-kinase activity and enhance intracellular phosphoinositide
3-kinase lipid products prior to ceramide generation. Dauno-
rubicin activates Akt, a downstream phosphoinositide 3-kinase
effector. Interestingly, the phosphoinositide 3-kinase inhibitors
wortmannin and LY294002 accelerate daunorubicin-induced
apoptosis in U937 cells. The phosphoinositide 3-kinase/Akt
pathway has been involved in cell survival following serum
deprivation, tumor necrosis factor K, anti-Fas and UV radia-
tions. Our results suggest that anti-tumor agents such as
daunorubicin may also activate anti-apoptotic signals that could
contribute to drug resistance.
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1. Introduction
Daunorubicin (DNR), an anthracycline widely used in the
treatment of acute myeloid leukemia (AML), induces apopto-
sis in some but not all myeloid leukemic cells. For example,
DNR at 0.5^1 WM induces internucleosomal DNA fragmen-
tation and morphological changes characteristic of apoptosis
in U937 and HL-60 cells [1]. The nature of the signaling path-
ways which initiate DNR-triggered apoptosis is still debated.
We have reported that at these concentrations, DNR stimu-
lates sphingomyelin (SM) hydrolysis and subsequent ceramide
generation due to neutral sphingomyelinase (SMase) activa-
tion [2]. The role of ceramide released from SM hydrolysis in
DNR-induced apoptosis was supported by further studies in-
dicating that SMase inhibition results not only in the inhib-
ition of ceramide generation but also in the inhibition of
apoptosis in DNR-treated cells [3,4]. The SM cycle is a com-
mon apoptotic signaling pathway shared by many other cyto-
toxic agents including vincristine, tumor necrosis factor K
(TNFK), CD95 agonists and radiations [5].
These studies and others emphasize the role of ceramide as
a key mediator in DNR-induced apoptosis. However, ceram-
ide-induced apoptosis is controlled by several factors includ-
ing Bcl-2 expression [6] and protein kinase C (PKC) activity
[7]. Therefore, external or intracellular stimuli which result in
Bcl-2 overexpression and/or PKC stimulation may limit the
DNR-induced apoptosis and cytotoxicity. Previous studies
have reported that doxorubicin activates PKC in various
cell systems [8] and stimulates phospholipase C and subse-
quent diacylglycerol (DAG) production in melanoma cells
[9]. These observations raise the intriguing possibility that
anthracyclines interfere with several membrane-associated en-
zyme activities which initiate either cell death or survival sig-
nals and that the balance between these two opposite path-
ways may in£uence the cellular response.
Among other enzymes which are involved in signal trans-
duction pathways, phosphoinositide 3-kinase (PI3K) plays an
important role. PI3Ks are a family of enzymes that catalyze
the phosphorylation of inositol lipids at the D3 position of the
inositol ring, generating new intracellular second messengers
[10]. The lipid products of PI3K are phosphatidylinositol-3-
phosphate (PtdIns-3-P), phosphatidylinositol-3,4-bisphos-
phate (PtdIns-3,4-P2) and phosphatidylinositol-3,4,5-trisphos-
phate (PtdIns-3,4,5-P3). In vivo, PtdIns-3,4-P2 and PtdIns-
3,4,5-P3 have been demonstrated to interact with downstream
e¡ectors. They act directly or indirectly on serine/threonine
kinase Akt which has been involved in the regulation of cell
survival (for a review, see [11]). In addition, PtdIns-3,4-P2 and
PtdIns-3,4,5-P3 stimulate calcium-insensitive novel PKC N, O,
R isoforms [12] as well as the atypical PKC j isoform [13]. The
use of PI3K inhibitors, wortmannin (WM) and LY294002 and
PI3K mutants has allowed us to demonstrate a role for PI3K
in the cell survival after various stresses including serum dep-
rivation [14,15], ionizing radiation [16], UV irradiation [17],
TNFK [18] and CD-95 [19].
We hypothesized that the stress induced by DNR could
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stimulate PI3K activity that might, in turn, in£uence drug-
induced apoptosis.
2. Materials and methods
2.1. Chemicals and antibodies
DNR was purchased from Roger Bellon (Neuilly/Seine, France).
LY294002 was provided by Calbiochem (Meudon, France). All other
reagents were obtained from Sigma (St-Quentin Fallavier, France).
Polyclonal antibody anti-p85 (06-195) was purchased from UBI
(Euromedex, Sou¡elweyersheim, France). Polyclonal Akt (phospho-
rylation state-independent) and phospho-speci¢c Akt (Ser-473) were
provided by New England Biolabs (Ozyme, Montigny le Bretonneux,
France). [Q-32P]ATP (7000 Ci/mmol) and [32P]orthophosphate were
obtained from ICN (Orsay, France).
2.2. Leukemic cell lines
The monocytic U937 cell line was obtained from the ATCC (Rock-
ville, MD, USA) and was cultured in RPMI supplemented with 10%
fetal calf serum (FCS), 2 mM glutamine and penicillin/streptomycin.
2.3. In vitro lipid kinase assay
In vitro lipid kinase was assayed as previously described [20].
Brie£y, exponentially growing cells were incubated in RPMI contain-
ing 1% FCS overnight. Cells were then incubated in serum-free RPMI
with or without WM (100 nM) for 30 min. After various times of
incubation with DNR, PI3K was immunoprecipitated prior to the
assay. After washing, the pellets were resuspended in 30 Wl bu¡er 1
(20 mM N-2-hydroxyethylpiperazine-NP-2-ethanesulfonic acid
(HEPES), 0.4 mM EDTA and 0.4 mM Na2HPO4). 10 Wl of 1 mg/
ml phosphatidylinositol previously sonicated and 10 Wl reaction bu¡er
(10 mM MgCl2, 50 WM ATP containing 0.3 WCi/sample of [Q-32P]ATP
in bu¡er 1) were incubated with the enzyme for 10 min at room
temperature. The reaction was stopped by the addition of 15 Wl of
4 N HCl. Lipids were extracted with methanol/chloroform (1:1, v/v).
Lipids in the organic phase were separated by thin layer chromatog-
raphy (TLC). After autoradiography, the PtdIns-3-P fractions were
scraped o¡ and the incorporated radioactivity was assayed by scintil-
lation counting.
2.4. Intracellular PtdIns-3,4-P2 and PtdIns-3,4,5-P3 assay
Exponentially growing cells were incubated overnight in RPMI
containing 1% FCS. They were incubated in serum- and phosphate-
free RPMI for 4 h with 0.5 Ci/mmol [32P]orthophosphate at 37‡C,
then washed with serum- and phosphate-free bu¡er before the addi-
tion of WM (100 nM for 30 min) and/or DNR (1 WM for di¡erent
times). The reaction was stopped by the addition of 2.4 N HCl at 4‡C.
Lipids were extracted and analyzed as previously described [21]. For
PtdIns-3,4,5-P3 level measurements, lipids were separated by TLC and
radiolabelled PtdIns-3,4,5-P3 was scraped o¡, separated and analyzed
by high performance liquid chromatography (HPLC) on a Parti-
sphere-SAX anion exchange column [22].
2.5. Akt activation
U937 cells were treated as for the lipid kinase activity. After various
times of incubation, cells were lysed and total cell proteins were sep-
arated in a 7.5% SDS-polyacrylamide gel and transferred on nitro-
cellulose. Activated Akt (phosphorylated on Ser-473) was detected
using a phospho-speci¢c Akt antibody and normalized to the total
Akt after probing with an Akt antibody independent of the phospho-
rylation status [23].
2.6. DNA ladders
Exponentially growing cells were pre-incubated overnight in RPMI
containing 1% FCS, then pre-treated or not with WM (50 and
100 nM) or LY294002 (10 and 25 WM) in serum-free RPMI for
30 min. DNR at 0.2 or 1 WM was added to the cells for 1 h. After
washing, cells were incubated in DNR-free medium in the presence or
absence of PI3K inhibitors for 3 or 5 h. After cell centrifugation at
20 000Ug, the pellets were incubated in lysis bu¡er (10 mM Tris-HCl,
10 mM EDTA, 10 mM NaCl, 0.5% SDS and 0.5 mg/ml proteinase K)
for 1 h at 50‡C, then with RNAse A for 2 h at 50‡C. After precip-
itation, DNA was electrophoresed in a 1.8% agarose gel in TBE at
50 V. The photographs of gels stained with ethidium bromide were
recorded.
3. Results
3.1. DNR activates p85/p110 PI3K in U937 cells
To determine whether PI3K could play a role in cell fate
after DNR treatment, we ¢rst investigated whether DNR
could stimulate a PI3K activity in U937 cells. PI3K activation
was determined by assaying the in vitro lipid kinase activity in
p85 immunoprecipitates. The results showed a rapid but mod-
erate (2-fold) increase in the PI3K activity induced by 1 WM
DNR (Fig. 1A). At 10 min, the PI3K activity returned to the
basal level. Similar experiments were conducted in the pres-
ence of the PI3K inhibitor WM. A pretreatment with 100 nM
WM for 30 min inhibited the basal and DNR-induced PI3K
activity by 80^90% (Fig. 1B).
We examined the dose-response e¡ect of DNR on the PI3K
activity. At a low DNR concentration (0.1 WM), a moderate
PI3K activation started 5 min after DNR treatment and was
sustained at 10 min, while it declined back to the basal level at
30 min (Fig. 1C). A second peak of activation occurred be-
tween 1 and 2 h. At 3 h, PI3K drastically decreased and
returned to the basal level (data not shown). At DNR con-
centrations comprised between 0.2 and 1 WM, the PI3K activ-
Fig. 1. Time-course and dose-response of lipid kinase activation by
DNR. (A) U937 cells were treated with 1 WM DNR. Cells were
lysed at the indicated time and the lysates were immunoprecipitated
with anti-p85 antibody. Following reaction with PtdIns and
[Q-32P]ATP, the phospholipids were separated by TLC, before auto-
radiography (Or: origin). (B) U937 cells were pre-incubated with
100 nM WM for 30 min, before DNR addition. (C) U937 cells
were treated with DNR at 0.1 WM (open square), 0.2 WM (open tri-
angle), 1 WM (closed square), 2 WM (closed triangle). Data in A and
B are from one experiment representative of 4^6 experiments. Data
in C are the mean þ S.D. of 4^6 independent experiments.
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ity was stimulated earlier (2 min). The 1.6^2-fold increase
occurred between 2 and 5 min and then declined at 10 min.
A second peak started at 15 min. A high level of PI3K activity
was maintained for 2 h, then, the PI3K activity was drastically
reduced (Fig. 1C) and remained low (data not shown). Higher
DNR concentrations were not able to signi¢cantly stimulate
PI3K activity, suggesting a dose-dependent e¡ect of DNR
such as previously observed on ceramide generation [2].
3.2. DNR induces the intracellular accumulation of
PtdIns-3,4-P2 and PtdIns-3,4,5-P3
To determine whether the lipid products resulting from
PI3K activity were increased in DNR-treated cells, we meas-
ured the levels of these lipids in U937 cells treated by 1 WM
DNR after separation by HPLC. The addition of DNR to
U937 cells resulted in a transient accumulation of PtdIns-
3,4,5-P3 and PtdIns-3,4-P2 (Fig. 2). The increase in PtdIns-
3,4-P2 levels was higher but the kinetics of PtdIns-3,4-P2 ac-
cumulation were slower than that of PtdIns-3,4,5-P3. The re-
sults are expressed relative to basal levels of PtdIns-3,4-P2
(1003 þ 182 cpm) and PtdIns-3,4,5-P3 (1384 þ 449 cpm). Com-
pared with the control status, the PtdIns-3,4-P2/PtdIns-4,5-P2
ratio was increased by a factor of two and six at 2 and 5 min,
respectively, then declined back to the basal level at 10 min
(data not shown). Pretreatment with 100 nM WM decreased
the basal levels of PtdIns-3,4-P2 and PtdIns-3,4,5-P3 by 80
and 70%, respectively (data not shown).
3.3. Akt is activated by DNR addition to U937 cells
Akt has been described as a downstream e¡ector of PI3K in
a number of models that involve activation of PI3K in sur-
vival signaling. We investigated whether Akt could be acti-
vated in U937 cells in response to DNR. The activation of
Akt is dependent on phosphorylation at two sites, Ser-473 and
Thr-308. We measured the extent of Akt activation using an
antibody speci¢c of phosphorylated Akt at Ser-473 [24]. DNR
at 0.2 or 1 WM increased the levels of the phosphorylated Akt
form at 5 min (Fig. 3A and B). The levels of phosphorylated
Akt expression declined back to the basal level at 15^30 min
and did not increase at longer times (data not shown). Pre-
treatment with 100 nM WM or 25 WM LY294002 inhibited
the expression of the Akt activated form following DNR
treatment by 90^95% (data not shown). These results show
that Akt is a downstream e¡ector of the DNR-induced acti-
vation of PI3K.
3.4. Inhibition of PI3K accelerates cell death by apoptosis
We tested whether PI3K inhibitors could alter DNR-trig-
gered apoptosis in human myeloid cells. Apoptosis character-
ized by DNA ladders has been described in U937 cells 6 h
after 1 WM DNR treatment [1]. However, WM pretreatment
accelerated DNA fragmentation. At 4 h, DNA ladders were
observed in DNR-treated U937 cells pre-treated with 100 nM
Fig. 2. DNR-induced generation of PI3K lipid products in U937
cells. After labelling with [32P]orthophosphate for 4 h, cells were
treated with 1 WM DNR. At the indicated time, cells were lysed and
lipids were extracted. PtdIns-3,4-P2 (open square) and PtdIns-3,4,5-
P3 (closed triangle) levels were determined after HPLC and TLC
prior to HPLC separation, respectively. The data are means þ S.D.
from three and ¢ve independent experiments, respectively.
Fig. 3. DNR-induced activation of Akt. (A) U937 cells were treated
with 1 WM DNR. Cells were lysed and proteins were separated on
7.5% SDS-PAGE, transferred to nitrocellulose and immunoblotted
with Akt and phospho-speci¢c Akt antibodies. (B) The phosphoryl-
ated Akt bands were quanti¢ed by a phosphorimager Storm-System
analysis using Imagequant software and normalized to the amounts
of total Akt. The data shown in B are means þ S.D. of three inde-
pendent experiments.
Fig. 4. E¡ects of WM and LY294002 on DNR-induced apoptosis in
U937 cells. Internucleosomal DNA fragmentation was determined in
U937 cells pre-incubated or not with WM (50 or 100 nM) or
LY294002 (LY) (10 or 25 WM), then treated with 1 WM DNR and
further incubated with DNR-free medium with or without PI3K in-
hibitors (A) for 4 h, (B) for 6 h. The data in A and B are from one
experiment representative of three independent experiments.
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WM or 25 WM LY294002, while no ladder was observed after
cell treatment with DNR or inhibitors alone (Fig. 4A). At 6 h,
PI3K inhibitors alone did not induce DNA fragmentation but
DNA ladders were observed in DNR-treated cells and ampli-
¢ed in WM- or LY294002-pre-treated cells even at lower in-
hibitor concentrations (Fig. 4B).
4. Discussion
Our study shows that DNR enhanced the in vitro lipid
kinase activity as well as the generation of lipid products of
PI3K in U937 cells. PtdIns-3,4,5-P3 synthesis was rapid and
transient and PtdIns-3,4-P2 accumulation was slightly de-
layed. Although PI3K activation and generation of its lipid
products were moderate compared to those observed for ex-
ample following growth factor addition, this increase was re-
producibly observed. The ¢rst peak of lipid kinase activation
was transient and concomitant with the appearance of lipid
products. A 2-fold stimulation of the in vitro lipid kinase
activity was also observed 2^5 min after DNR addition in
the HL-60 myeloid cell line, indicating that PI3K activation
is not restricted to the U937 cell model (data not shown). A
second activation was maintained for about 2 h and had no
e¡ect on Akt activation. Interestingly, the PI3K activity dras-
tically decreased at 3 h, prior to DNA fragmentation and
PARP cleavage. Except at 0.1 WM, this was not reversible.
The mechanisms by which DNR stimulates PI3K are unclear.
Whether DNR interferes with the tyrosine phosphorylation
status of receptor tyrosine kinases, intracellular substrates
such as insulin receptor substrate-1 (IRS-1) or Src family pro-
teins, as previously shown for other stimuli, has not been
investigated yet. However, radical oxygen species (ROS)
may interfere with the function of proteins known to interact
with PI3K. Exposure to H2O2 results in tyrosine phosphoryl-
ation of IRS-1 and its speci¢c association with the p85 adap-
tor of PI3K activates p21Ras [24] which may interact directly
with the p110-PI3K [25]. H2O2 also induces tyrosine phos-
phorylation of pp60c-src and PDGFL receptor [26]. There-
fore, the oxidative stress generated by DNR [27] may play a
role in PI3K activation. Such hypotheses are currently under
study in our laboratory.
Our results suggest that the PI3K activation plays a role in
DNR-treated leukemic cells. We failed to observe a signi¢cant
e¡ect of two di¡erent PI3K inhibitors on the cell clonogenic-
ity after DNR treatment. However, we showed that PI3K
inhibitors facilitated apoptosis in U937 cells. Internucleoso-
mal DNA fragmentation was accelerated by pretreatment
with inhibitors in DNR-treated U937 cells. DNR-induced
poly(ADP-ribose)polymerase cleavage, another speci¢c event
of apoptosis, was also accelerated in the presence of PI3K
inhibitors (data not shown). Moreover, PI3K activation was
abolished after 3 h, suggesting PI3K inhibition when cells are
engaged in apoptosis. These results suggest a protective role
for PI3K activation and are in agreement with those previ-
ously described with UV-, TNFK- and anti-Fas-induced apop-
tosis [17,18].
The DNR-induced PI3K activation appeared to be much
lower than that observed after transfection of oncogenes [28]
or cytokine stimulation [29]. However, one can speculate that
PI3K could impair DNR-induced apoptosis and/or cytotox-
icity. The fact that BCR/ABL transfection inhibits DNR-in-
duced apoptosis [30] and confers resistance to DNR (and to
other compounds) supports the general idea that a sustained
PI3K activation may be involved in drug resistance.
Our study showed that DNR activated Akt and that Akt
activation was inhibited in a PI3K-dependent manner. This
activation occurred in response to the earlier peak of PI3K
activation. In response to growth factors, PtdIns-3,4-P2 and
PtdIns-3,4,5-P3 can interact with Akt. This interaction most
likely plays a role in the translocation of Akt to the membrane
where it can be activated by upstream kinases [31] also regu-
lated by PI3K lipid products [32]. Although the function of
Akt is not fully understood, most recent studies suggest a role
for Akt in the cell survival [17,33]. The ¢nding that H2O2-
induced Akt activation is dependent on PI3K [34] supports a
role for DNR-induced ROS in the DNR-triggered PI3K/Akt
pathway. The mechanisms by which Akt exerts its protective
function are still under investigation. It has been proposed
that Akt could regulate the Bcl-2 expression [35]. In our mod-
el, PI3K inhibitors did not change the Bcl-2 expression follow-
ing cell exposure to DNR (data not shown), indicating that
Bcl-2 expression is not controlled by the PI3K/Akt pathway.
Similar conclusions were reported by Hay and colleagues
[15,23]. Recently, it has been proposed that Akt phosphoryl-
ates and inhibits BAD, a pro-apoptotic member of the Bcl-2
family, by cytosolic sequestration and prevention of binding
to Bcl-xL [36]. This hypothesis is under current investigation
in our laboratory. Another mechanism involves inhibition of
Ced3/ICE-like activity by PI3K and Akt [16] while PI3K in-
hibition enhanced caspase 3 activation [18]. Whether PI3K
could regulate caspase activation during DNR-induced apop-
tosis in myeloid cells needs to be investigated.
In summary, our study shows that DNR activates the
PI3K/Akt pathway and that PI3K inhibitors accelerate
DNR-induced apoptosis. The control of PI3K activity could
be an attractive way to modulate the cytotoxicity of chemo-
therapeutic drugs in cancer cells.
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